{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T18:13:16Z","timestamp":1773079996300,"version":"3.50.1"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circulation"],"published-print":{"date-parts":[[1997,4,15]]},"abstract":"<jats:p>\n            <jats:italic>Background<\/jats:italic>\n            The Intracoronary Stenting and Antithrombotic Regimen (ISAR) Trial is a randomized study in which antiplatelet therapy is compared with anticoagulant therapy after coronary stent placement, showing a significantly lower rate of noncardiac and cardiac events with antiplatelet therapy. The present study is a report of the analysis of a prospective risk stratification protocol in the ISAR Trial and the association with the incidence of adverse cardiac events and stent vessel occlusion.\n          <\/jats:p>\n          <jats:p>\n            <jats:italic>Methods and Results<\/jats:italic>\n            In all 517 patients randomized in the ISAR Trial, risk stratification was done with a list of 18 clinical, procedural, and angiographic variables: 165 patients with two or fewer criteria were classified as low risk, 148 patients with three criteria were classified as intermediate risk, and 204 patients with four or more criteria were classified as high risk. Within a 30-day follow-up, cardiac event rate (death, myocardial infarction, repeat intervention) was 6.4% for high-risk, 3.4% for intermediate-risk, and 0% for low-risk patients (\n            <jats:italic>P<\/jats:italic>\n            &lt;.01). Stent vessel occlusion occurred in 5.9%, 2.7%, and 0%, respectively (\n            <jats:italic>P<\/jats:italic>\n            &lt;.01). There was no significant difference between anticoagulant and antiplatelet therapy in the low- and intermediate-risk groups. In high-risk patients, however, the cardiac event rate was 12.6% with anticoagulant therapy and 2.0% with antiplatelet therapy (\n            <jats:italic>P<\/jats:italic>\n            =.007), and the rate of stent vessel occlusion was 11.5% and 0%, respectively (\n            <jats:italic>P<\/jats:italic>\n            &lt;.001).\n          <\/jats:p>\n          <jats:p>\n            <jats:italic>Conclusions<\/jats:italic>\n            This risk stratification protocol can help to identify patients at risk for adverse cardiac events and stent vessel occlusion. Patients in the high-risk group had the most benefit from antiplatelet therapy. These data suggest that antiplatelet therapy is the therapy of choice after coronary stenting specifically for patients with acute ischemic syndromes, difficult procedures, or suboptimal final results.\n          <\/jats:p>","DOI":"10.1161\/01.cir.95.8.2015","type":"journal-article","created":{"date-parts":[[2012,6,12]],"date-time":"2012-06-12T00:41:02Z","timestamp":1339461662000},"page":"2015-2021","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":69,"title":["Major Benefit From Antiplatelet Therapy for Patients at High Risk for Adverse Cardiac Events After Coronary Palmaz-Schatz Stent Placement"],"prefix":"10.1161","volume":"95","author":[{"given":"Helmut","family":"Schu\u0308hlen","sequence":"first","affiliation":[{"name":"From the 1. Medizinische Klinik (H.S., M.H., H.W., A.S.) and Institut fu\u0308r Medizinische Statistik und Epidemiologie (K.U.), Klinikum rechts der Isar, Technische Universita\u0308t Mu\u0308nchen, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Hadamitzky","sequence":"additional","affiliation":[{"name":"From the 1. Medizinische Klinik (H.S., M.H., H.W., A.S.) and Institut fu\u0308r Medizinische Statistik und Epidemiologie (K.U.), Klinikum rechts der Isar, Technische Universita\u0308t Mu\u0308nchen, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna","family":"Walter","sequence":"additional","affiliation":[{"name":"From the 1. Medizinische Klinik (H.S., M.H., H.W., A.S.) and Institut fu\u0308r Medizinische Statistik und Epidemiologie (K.U.), Klinikum rechts der Isar, Technische Universita\u0308t Mu\u0308nchen, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kurt","family":"Ulm","sequence":"additional","affiliation":[{"name":"From the 1. Medizinische Klinik (H.S., M.H., H.W., A.S.) and Institut fu\u0308r Medizinische Statistik und Epidemiologie (K.U.), Klinikum rechts der Isar, Technische Universita\u0308t Mu\u0308nchen, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"Scho\u0308mig","sequence":"additional","affiliation":[{"name":"From the 1. Medizinische Klinik (H.S., M.H., H.W., A.S.) and Institut fu\u0308r Medizinische Statistik und Epidemiologie (K.U.), Klinikum rechts der Isar, Technische Universita\u0308t Mu\u0308nchen, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_2_1_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198703193161201"},{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(93)90827-N"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.90.6.7994813"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199408253310802"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199408253310801"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199408253310811"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.83.1.1984878"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.94.7.1519"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.91.6.1676"},{"key":"e_1_3_2_10_2","first-page":"782","volume":"28","year":"1996","unstructured":"Pepine CJ, Holmes DR, Block PC, Brinker JA, Mark DB, Mullins CE, Nissen SE, Topol EJ, Williams DO, Goldberg S, Hirshfeld JW, Serruys PW. ACC Expert Consensus Document: coronary artery stents. J Am Coll Cardiol. 1996;28:782-794.","journal-title":"J Am Coll Cardiol"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199604253341702"},{"key":"e_1_3_2_12_2","first-page":"1216","volume":"73","year":"1995","unstructured":"Agrawal SK, Ho DSW, Liu MW, Iyer SS, Hearn JA, Cannon AD, Macander PJ, Dean LS, Baxley WA, Roubin GS. Predictors of thrombotic complications following placement of the flexible coil stent. Am J Cardiol. 1995;73:1216-1219.","journal-title":"Am J Cardiol"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(95)90228-7"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(94)90004-3"},{"key":"e_1_3_2_15_2","unstructured":"Lincoff AM Topol EJ. Abrupt vessel closure. In Topol EJ ed. Textbook of Interventional Cardiology. Philadelphia Pa: WB Saunders; 1990:207-230."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.82.4.2401060"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.80.3.2527641"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","unstructured":"Hosmer DW Lemeshow S. Applied Logistic Regression. New York NY: John Wiley & Sons; 1989.","DOI":"10.2307\/2531779"},{"key":"e_1_3_2_19_2","unstructured":"Robertson T Wright FT Dykstra RL. Order Restricted Statistical Inference. New York NY: John Wiley & Sons; 1988."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(93)90093-G"}],"container-title":["Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/01.CIR.95.8.2015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T16:10:41Z","timestamp":1715530241000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/01.CIR.95.8.2015"}},"subtitle":["Analysis of a Prospective Risk Stratification Protocol in the Intracoronary Stenting and Antithrombotic Regimen (ISAR) Trial"],"short-title":[],"issued":{"date-parts":[[1997,4,15]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[1997,4,15]]}},"alternative-id":["10.1161\/01.CIR.95.8.2015"],"URL":"https:\/\/doi.org\/10.1161\/01.cir.95.8.2015","relation":{},"ISSN":["0009-7322","1524-4539"],"issn-type":[{"value":"0009-7322","type":"print"},{"value":"1524-4539","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,4,15]]},"assertion":[{"value":"1996-09-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"1996-11-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"1997-04-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}